BriaCell Therapeutics Corp. (BCT.TO)
5.31
-0.30
(-5.35%)
CAD |
TSX |
Oct 13, 16:00
BriaCell Therapeutics Enterprise Value : 6.578M for Oct. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 13, 2026 | 6.578M |
| October 09, 2026 | 8.753M |
| October 08, 2026 | 8.390M |
| October 07, 2026 | 9.333M |
| October 06, 2026 | 9.405M |
| October 05, 2026 | 11.07M |
| October 02, 2026 | 9.768M |
| October 01, 2026 | 10.71M |
| September 30, 2026 | 12.31M |
| September 29, 2026 | 10.13M |
| September 28, 2026 | 9.623M |
| September 25, 2026 | 11.87M |
| September 24, 2026 | 11.73M |
| September 23, 2026 | 9.115M |
| September 22, 2026 | 9.695M |
| September 21, 2026 | 10.13M |
| September 18, 2026 | 10.93M |
| September 17, 2026 | 11.00M |
| September 16, 2026 | 4.185M |
| September 15, 2026 | 3.750M |
| September 14, 2026 | 4.185M |
| September 11, 2026 | 4.620M |
| September 10, 2026 | 4.257M |
| September 09, 2026 | 4.692M |
| September 08, 2026 | 3.242M |
| Date | Value |
|---|---|
| September 04, 2026 | 3.822M |
| September 03, 2026 | 3.387M |
| September 02, 2026 | 3.967M |
| September 01, 2026 | 4.692M |
| August 31, 2026 | 4.112M |
| August 28, 2026 | 5.708M |
| August 27, 2026 | 5.49M |
| August 26, 2026 | 8.825M |
| August 25, 2026 | 5.345M |
| August 24, 2026 | 3.025M |
| August 21, 2026 | 8.390M |
| August 20, 2026 | 7.810M |
| August 19, 2026 | 7.593M |
| August 18, 2026 | 3.242M |
| August 17, 2026 | 2.155M |
| August 14, 2026 | 2.372M |
| August 13, 2026 | 2.880M |
| August 12, 2026 | 2.445M |
| August 11, 2026 | 2.735M |
| August 10, 2026 | 2.300M |
| August 07, 2026 | 4.837M |
| August 06, 2026 | 3.242M |
| August 05, 2026 | 3.822M |
| August 04, 2026 | 2.227M |
| July 31, 2026 | 3.025M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Kane Biotech, Inc. | 6.235M |
| Quest PharmaTech, Inc. | 4.368M |
| Vaxil Bio Ltd. | 0.1137M |
| Waverley Pharma, Inc. | 4.099M |
| Goldcoast Resource Corp. | 0.6993M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.920M |
| Total Expenses (Quarterly) | 9.820M |
| EPS Diluted (Quarterly) | -1.354 |
| Earnings Yield | -317.7% |
| Normalized Earnings Yield | -324.24 |